---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-25-000018"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:56:13.164596+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evolent Q4 2024 revenue $646.5M (+16.3% YoY); net loss $30.6M, adjusted EBITDA $22.6M

## Summary
- Revenue $2,554.7M full year 2024, +30.1% YoY; net loss $93.5M, net loss margin (3.7)%.
- Adjusted EBITDA $160.5M full year 2024, margin 6.3%; Q4 adjusted EBITDA $22.6M, margin 3.5%.
- Signed contract amendments in all three Performance Suite negotiations, expected $115M annual improvement for 2025 vs Q4 2024.
- 100% retention across top customers representing over 90% of 2024 revenue; new revenue agreements announced in Q4.
- Average Performance Suite lives on platform 7,145 in Q4, average PMPM fee $21.32.

## SEC filing metadata
- accession: 0001628908-25-000018
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890825000018/0001628908-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890825000018/evh-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-25-000018
- JSON: https://secwatch.observer/filing/0001628908-25-000018.json
- Plain text: https://secwatch.observer/filing/0001628908-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.